Spoken Alpha
GRUSF
Grown Rogue International Inc.
Overview
Grown Rogue International Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $108.7M market cap.
Most recent reported earnings: Q3 FY2025 (Nov 10, 2025).
3 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q3 FY20252025-11-10EPS$0.01 vs $0.00—Rev$8.8M vs ——EODHD
- Q1 FY20252025-05-12EPS$-0.01 vs $0.00—Rev$5.6M vs ——EODHD
- Q4 FY20242024-12-30EPS$0.01 vs ——Rev$5.7M vs ——EODHD
- Q3 FY20242024-09-29EPS$-0.00 vs ——Rev$7.0M vs ——EODHD
- Q2 FY20242024-05-28EPS$-0.04 vs ——Rev$7.7M vs ——EODHD
- Q1 FY20242024-02-26EPS$-0.01 vs ——Rev$6.4M vs ——EODHD
- Q4 FY20232023-12-18EPS$-0.01 vs $0.00—Rev$6.5M vs ——EODHD
- Q3 FY20232023-09-25EPS$0.00 vs ——Rev$6.3M vs ——EODHD
- Q2 FY20232023-06-18EPS$0.00 vs ——Rev$6.0M vs ——EODHD
- Q1 FY20232023-03-26EPS$-0.00 vs ——Rev$4.5M vs ——EODHD
- Q4 FY20222023-01-30EPS$-0.00 vs ——Rev$5.1M vs ——EODHD
- Q3 FY20222022-09-28EPS$0.00 vs ——Rev$4.3M vs ——EODHD
- Q2 FY20222022-06-27EPS$0.01 vs ——Rev$4.7M vs ——EODHD
- Q1 FY20222022-03-31EPS$-0.00 vs ——Rev$3.7M vs ——EODHD
- Q3 FY20212021-09-28EPS$0.00 vs ——Rev$3.0M vs ——EODHD
- Q2 FY20212021-06-28EPS$-0.01 vs ——Rev$1.5M vs ——EODHD
- Q1 FY20212021-03-31EPS$-0.01 vs ——Rev$1.1M vs ——EODHD
- Q3 FY20202020-09-28EPS$-0.01 vs ——Rev$904.0K vs ——EODHD
- Q2 FY20202020-06-28EPS$-0.01 vs ——Rev$1.2M vs ——EODHD
- Q1 FY20202020-03-19EPS$-0.00 vs ——Rev$1.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2025 | 2025-11-10 | $0.01 | $0.00 | — | $8.8M | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.01 | $0.00 | — | $5.6M | — | — | EODHD |
| Q4 FY2024 | 2024-12-30 | $0.01 | — | — | $5.7M | — | — | EODHD |
| Q3 FY2024 | 2024-09-29 | $-0.00 | — | — | $7.0M | — | — | EODHD |
| Q2 FY2024 | 2024-05-28 | $-0.04 | — | — | $7.7M | — | — | EODHD |
| Q1 FY2024 | 2024-02-26 | $-0.01 | — | — | $6.4M | — | — | EODHD |
| Q4 FY2023 | 2023-12-18 | $-0.01 | $0.00 | — | $6.5M | — | — | EODHD |
| Q3 FY2023 | 2023-09-25 | $0.00 | — | — | $6.3M | — | — | EODHD |
| Q2 FY2023 | 2023-06-18 | $0.00 | — | — | $6.0M | — | — | EODHD |
| Q1 FY2023 | 2023-03-26 | $-0.00 | — | — | $4.5M | — | — | EODHD |
| Q4 FY2022 | 2023-01-30 | $-0.00 | — | — | $5.1M | — | — | EODHD |
| Q3 FY2022 | 2022-09-28 | $0.00 | — | — | $4.3M | — | — | EODHD |
| Q2 FY2022 | 2022-06-27 | $0.01 | — | — | $4.7M | — | — | EODHD |
| Q1 FY2022 | 2022-03-31 | $-0.00 | — | — | $3.7M | — | — | EODHD |
| Q3 FY2021 | 2021-09-28 | $0.00 | — | — | $3.0M | — | — | EODHD |
| Q2 FY2021 | 2021-06-28 | $-0.01 | — | — | $1.5M | — | — | EODHD |
| Q1 FY2021 | 2021-03-31 | $-0.01 | — | — | $1.1M | — | — | EODHD |
| Q3 FY2020 | 2020-09-28 | $-0.01 | — | — | $904.0K | — | — | EODHD |
| Q2 FY2020 | 2020-06-28 | $-0.01 | — | — | $1.2M | — | — | EODHD |
| Q1 FY2020 | 2020-03-19 | $-0.00 | — | — | $1.1M | — | — | EODHD |
Source: EODHD. GRUSF reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks GRUSF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.25 | $1.44 | -13.0% | -3.9% | -3.9% |
| Q4 FY2026 | $1.41 | $1.59 | -11.4% | +0.3% | -2.0% |
| Q3 FY2026 | $1.46 | $1.56 | -6.3% | -1.1% | +1.4% |
| Q2 FY2026 | $1.41 | $1.49 | -5.6% | -7.6% | -7.7% |
| Q1 FY2025 | $1.26 | $1.54 | -18.1% | -4.7% | -7.3% |
| Q4 FY2025 | $1.32 | $1.48 | -11.1% | +0.8% | +2.0% |
| Q3 FY2025 | $1.39 | $1.57 | -11.3% | -3.6% | -4.6% |
| Q2 FY2025 | $1.32 | $1.48 | -10.6% | +1.6% | -0.9% |
| Q1 FY2024 | $1.41 | $1.57 | -10.3% | +0.7% | -1.8% |
| Q4 FY2024 | $1.41 | $1.66 | -14.9% | -1.2% | -1.6% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GRUSF.
$ curl https://api.spokenalpha.com/v1/companies/GRUSFFAQ
Frequently asked about GRUSF
Where can I find Grown Rogue International Inc.'s (GRUSF) earnings call transcripts?
Spoken Alpha indexes GRUSF's earnings call transcripts at https://spokenalpha.com/companies/GRUSF. Each call links to attributed speakers and parsed analyst Q&A. Grown Rogue International Inc.'s own investor relations page is at https://www.grownrogue.com/investors.
When was Grown Rogue International Inc.'s most recent earnings call?
Grown Rogue International Inc. (GRUSF) held its most recent earnings call on 2026-05-12, covering fiscal Q1 2026.
What sector is GRUSF in?
Grown Rogue International Inc. (GRUSF) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).